Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

tislelizumab 1envafolimab 1durvalumab 1Nivolumab 1Neoadjuvant Therapy 1Circulating Tumor DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Rectal Carcinoma × tislelizumab × Clear all
NCT06312982 2026-01-13

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Beijing Friendship Hospital

Phase 2/3 Recruiting
375 enrolled
Gastrointestinal

Locally Advanced Rectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡